VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
KMPB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
KMPBKemper Corporation 5.875% Fixed
$23.95$1.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksKMPBFinancials

Kemper Corporation 5.875% Fixed (KMPB) Financials

30Y historyFree accessUpdated daily

Underwriting profitability remains under pressure as evidenced by the 2025Q4 combined ratio of 101.2% and a net loss of $4.4 million in 2026Q1.

KMPB Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Revenue4.71B4.8B4.63B4.95B5.45B5.61B5.18B5.02B3.69B2.67B2.52B2.34B2.2B2.43B2.46B2.5B2.64B2.93B2.74B2.9B2.86B2.83B2.82B2.67B2.3B2.53B1.95B1.81B2.09B1.56B1.57B
Revenue Growth %0.55%3.62%-6.32%-9.27%-2.92%8.42%3.16%36.13%38.17%5.83%7.74%6.56%-9.47%-1.45%-1.31%-5.58%-9.92%6.97%-5.54%1.6%0.99%0.36%5.62%16.14%-9.3%29.73%7.7%-13.05%34.12%-1.17%5.44%
Medical Costs & Claims3.22B3.38B4.04B3.82B5.66B5.26B4.02B3.83B2.92B2.23B2.16B1.83B1.59B1.7B1.94B2B1.65B1.74B1.77B2.28B2.22B2.29B2.49B2.58B2.16B1.84B1.65B1.46B1.29B1.26B1.29B
Medical Cost Ratio %68.37%70.32%87.28%77.25%103.88%93.68%77.58%76.3%79.2%83.54%85.82%78.07%72.2%70.2%78.74%80.22%62.33%59.3%64.37%78.47%77.72%80.77%88.4%96.85%94.12%72.69%84.43%80.65%61.82%81.05%81.71%
Gross Profit381.6M1.43B589.4M1.13B-211.3M354.8M1.16B1.19B766.9M439.2M357.5M513.4M610.7M723.1M523.5M493.6M995.3M1.19B977M624.9M636.5M544M326.9M84.2M135.2M691.9M304.1M350.9M796.4M294.8M287.8M
Gross Margin %8.11%29.68%12.72%22.75%-3.88%6.32%22.42%23.7%20.8%16.46%14.18%21.93%27.8%29.8%21.26%19.78%37.67%40.7%35.63%21.53%22.28%19.23%11.6%3.15%5.88%27.31%15.57%19.35%38.18%18.95%18.29%
Gross Profit Growth %-141.77%-47.62%632.56%-159.55%-69.44%-2.45%55.17%74.61%22.85%-30.37%-15.93%-15.54%38.13%6.06%-50.41%-16.63%22.2%56.34%-1.82%17%66.41%288.24%-37.72%-80.46%127.52%-13.34%-55.94%170.15%2.43%-80.72%
Operating Expenses340.7M1.26B200.9M1.47B159.7M604.2M650.8M528.4M567.8M278.1M354M413.1M450.5M408.7M401.1M425.3M758.6M964.3M1.07B398.1M266.5M232.4M213.1M199.9M159.8M149.4M-1.5B113.9M109.3M-1.13B-1.17B
OpEx / Revenue %7.24%26.34%4.34%29.77%2.93%10.76%12.57%10.53%15.4%10.42%14.04%17.65%20.51%16.84%16.29%17.05%28.71%32.87%38.91%13.71%9.33%8.21%7.56%7.49%6.95%5.9%-76.65%6.28%5.24%-72.7%-74.4%
Depreciation & Amortization-12.5M74.3M53.7M58.6M70.9M99.8M55M62.5M171.9M18.2M19.5M28.9M23.2M25.7M23.3M22.3M25.5M344.3M353.5M357.4M364.8M11.6M12.6M11.4M245.6M189.6M12.1M163.1M149.3M167.4M170.1M
Combined Ratio %75.61%96.65%91.61%107.02%106.81%104.44%90.15%86.82%94.6%93.96%99.86%95.72%92.71%87.04%95.03%97.26%91.04%92.17%103.28%92.19%87.05%88.99%95.96%104.33%101.07%78.59%7.78%86.93%67.06%8.35%7.31%
Operating Income33M160.7M388.5M-347.1M-371M-249.4M510.1M661.6M199.1M161.1M3.5M100.3M160.2M314.4M122.4M68.3M236.7M229.6M-90M226.8M370M311.6M113.8M-115.7M-24.6M542.5M1.8B237M687.1M1.43B1.46B
Operating Margin %0.7%3.35%8.39%-7.02%-6.81%-4.44%9.85%13.18%5.4%6.04%0.14%4.28%7.29%12.96%4.97%2.74%8.96%7.83%-3.28%7.81%12.95%11.01%4.04%-4.33%-1.07%21.41%92.22%13.07%32.94%91.65%92.69%
Operating Income Growth %--58.64%211.93%6.44%-48.76%-148.89%-22.9%232.3%23.59%4502.86%-96.51%-37.39%-49.05%156.86%79.21%-71.14%3.09%355.11%-139.68%-38.7%18.74%173.81%198.36%-370.33%-104.53%-69.88%660.04%-65.51%-51.8%-2.27%5.56%
EBITDA20.5M235M442.2M-288.5M-300.1M-149.6M565.1M724.1M371M179.3M23M129.2M183.4M340.1M145.7M90.6M262.2M573.9M263.5M584.2M734.8M323.2M126.4M-104.3M221M732.1M1.81B400.1M836.4M1.59B1.63B
EBITDA Margin %0.44%4.9%9.55%-5.83%-5.51%-2.66%10.91%14.42%10.06%6.72%0.91%5.52%8.35%14.02%5.92%3.63%9.92%19.56%9.61%20.12%25.72%11.42%4.48%-3.91%9.62%28.89%92.84%22.06%40.1%102.42%103.49%
Interest Expense36.4M38.5M56.9M56.1M54.7M43.6M36M42.5M43.4M34.9M44.4M46.5M46.9M38.1M37.6M36.9M68.3M241.6M321.3M398.1M62.5M64M57.4M45.3M26.9M22.2M151.9M113.9M109.3M129.8M115.1M
Non-Operating Income11.4M-38.5M-56.9M-56.1M-54.7M-43.7M-36M-42.5M-43.4M-34.9M-44.4M-46.5M-46.9M-38.1M-37.6M-36.9M-68.3M-241.6M-321.3M-398.1M-62.5M-64M-279.1M-319.9M-26.9M-22.2M1.65B-113.9M-109.3M1.3B1.34B
Pretax Income33M160.7M388.5M-347.1M-371M-249.3M510.1M661.6M199.1M161.1M3.5M100.3M160.2M314.4M122.4M68.3M236.7M229.6M-90M226.8M370M311.6M335.5M158.9M-24.6M542.5M145.4M237M687.1M165M172.7M
Pretax Margin %0.7%3.35%8.39%-7.02%-6.81%-4.44%9.85%13.18%5.4%6.04%0.14%4.28%7.29%12.96%4.97%2.74%8.96%7.83%-3.28%7.81%12.95%11.01%11.9%5.95%-1.07%21.41%7.44%13.07%32.94%10.61%10.97%
Income Tax1.8M28.1M76M-74.8M-84.4M-125.6M100.2M130.5M10.7M41.2M-9.2M20.1M47.6M99.9M30.6M6.6M67.5M66.4M-46.2M49.9M115M80.2M98.9M34.1M-18.3M190.3M54.4M77.9M238.6M47.1M40.2M
Effective Tax Rate %5.45%17.49%19.56%21.55%22.75%50.38%19.64%19.72%5.37%25.57%-262.86%20.04%29.71%31.77%25%9.66%28.52%28.92%51.33%22%31.08%25.74%29.48%21.46%74.39%35.08%37.41%32.87%34.73%28.55%23.28%
Net Income39.2M143.3M317.8M-272.1M-286.6M-123.7M409.9M531.1M190.1M120.9M16.8M85.7M114.5M217.7M103.4M74.5M184.6M164.7M-29.6M205.4M283.1M255.5M240.2M123.6M-8.2M380.9M91M201M510.8M117.9M132.5M
Net Margin %0.83%2.99%6.86%-5.5%-5.26%-2.2%7.92%10.58%5.15%4.53%0.67%3.66%5.21%8.97%4.2%2.99%6.99%5.61%-1.08%7.08%9.91%9.03%8.52%4.63%-0.36%15.03%4.66%11.08%24.49%7.58%8.42%
Net Income Growth %-88.68%-54.91%216.8%5.06%-131.69%-130.18%-22.82%179.38%57.24%619.64%-80.4%-25.15%-47.4%110.54%38.79%-59.64%12.08%656.42%-114.41%-27.45%10.8%6.37%94.34%1607.32%-102.15%318.57%-54.73%-60.65%333.25%-11.02%-12.02%
EPS (Diluted)0.672.294.91-4.25-4.72-1.886.147.963.242.330.331.652.123.801.741.382.982.64-0.473.124.153.673.481.82-0.125.601.322.746.511.561.74
EPS Growth %-89.44%-53.36%215.53%9.96%-151.06%-130.62%-22.86%145.68%39.06%606.06%-80%-22.17%-44.21%118.39%26.09%-53.69%12.88%661.7%-115.06%-24.82%13.08%5.46%91.21%1616.67%-102.14%324.24%-51.82%-57.91%317.31%-10.34%-5.95%
EPS (Basic)-2.314.95-4.25-4.72-1.886.248.043.272.340.331.652.123.811.751.382.982.64-0.473.134.173.703.511.83-0.125.641.322.766.551.581.76
Diluted Shares Outstanding58.8M62.61M64.78M64.03M63.83M64.26M66.73M66.55M58.75M51.58M51.21M51.68M53.87M56.98M59.43M60.26M61.77M62.16M62.68M65.83M68.22M69.62M69.02M67.91M68.33M68.02M68.94M73.36M78.46M75.58M76.15M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetHealthy
Cash FlowDeteriorating
Top Statement Risk

Underwriting volatility in specialty

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Top Line Contraction Amid Strategic Pivot

As indicated by the most recent quarterly filings, Kemper's revenue growth has shifted into negative territory, with a 7.0% decline in 2026Q1, reflecting the ongoing strategic exit from the Preferred P&C segment and the inherent challenges of maintaining volume in the non-standard auto market.

The contraction in revenue suggests that the company is prioritizing underwriting discipline over top-line expansion as it sheds lower-margin business. Investors should monitor whether this reduction in scale will eventually stabilize the premium base or if competitive pressures in the specialty segment will continue to erode the company's market share.

Underwriting Profitability Under Significant Pressure

Based on the reported financial data, the combined ratio deteriorated to 101.2% in 2025Q4, signaling that the company is currently failing to generate an underwriting profit and is instead relying on investment returns to offset core operational losses in its specialty insurance lines.

The volatility in the loss ratio, which spiked to 100.0% in 2025Q3, highlights the sensitivity of the specialty auto segment to inflationary repair costs and medical severity. This trend suggests that the company's current pricing models may be lagging behind the actual cost of claims, warranting further investigation into the efficacy of recent rate increases.

Operational Instability During Strategic Realignment

As evidenced by the swing from a 100.0% loss ratio in 2025Q3 to a net loss of $4.4 million in 2026Q1, the company appears to be in a period of significant operational transition that has obscured its underlying earnings power and created substantial volatility in quarterly results.

The transition away from the Preferred P&C segment represents a major inflection point that may improve long-term margins but currently introduces significant noise into the income statement. Analysts should remain cautious, as the lack of consistent underwriting profitability suggests that the company has not yet successfully navigated the transition to a leaner, specialty-focused model.

Structural Risks in Non-Standard Underwriting

According to the provided income statement data, the persistent inability to maintain a combined ratio consistently below 100% suggests that Kemper's specialty auto niche may be structurally disadvantaged by social inflation and rising claim severity that cannot be easily mitigated through standard rate adjustments.

The reliance on investment income to mask underwriting deficits appears to be a precarious strategy in an environment where claim costs are rising faster than earned premiums. This warrants further investigation into whether the company's agency-led distribution model is actually providing a competitive advantage or if it is simply trapping the firm in a high-cost, high-risk segment with limited pricing power.

KMPB — Frequently Asked Questions

Quick answers to the most common questions about buying KMPB stock.

What was Kemper Corporation 5.875% Fixed's (KMPB) revenue in 2025?

For fiscal year 2025, Kemper Corporation 5.875% Fixed (KMPB) reported total revenue of $4.80B. This represents a 205.0% increase compared to $1.57B in 1996.

Is Kemper Corporation 5.875% Fixed (KMPB) profitable?

Kemper Corporation 5.875% Fixed (KMPB) is profitable, generating $143.3M in net income for the fiscal year ending 2025 with a net profit margin of 3.0%.

What is Kemper Corporation 5.875% Fixed's operating profit margin?

Kemper Corporation 5.875% Fixed (KMPB) reported an operating income of $160.7M, resulting in an operating profit margin of 3.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Kemper Corporation 5.875% Fixed's gross profit and gross margin?

Kemper Corporation 5.875% Fixed (KMPB) generated $1.43B in gross profit for the year, representing a gross profit margin of 29.7%. This demonstrates the company's core pricing power and production efficiency.